Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, filed on Thursday with the SEC to raise up to $86 million in an initial public offering.
Close peer Versartis (VSAR) raised $126 million in its March IPO. Versartis...read more
Last week’s IPOs were up an average of 32% while the S&P 500 gained only 1%. Technology and health care companies (especially biotechs) continue to be the most...read more
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised $126 million by offering 6.0 million shares at $21, the high end of the revised $19 to $21 range. The company originally planned to offer 4.6 million shares at $16 to...read more
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more
Growth hormone biotech Ascendis Pharma files for a $86 million IPO
Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. Close peer Versartis (VSAR) raised $126 million in its March IPO. Versartis...read more
US IPO Recap: Year's largest biotech IPO Versartis jumps 49% amid tech-biotech frenzy
Last week’s IPOs were up an average of 32% while the S&P 500 gained only 1%. Technology and health care companies (especially biotechs) continue to be the most...read more
Versartis prices IPO at $21, the high end of the revised range
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised $126 million by offering 6.0 million shares at $21, the high end of the revised $19 to $21 range. The company originally planned to offer 4.6 million shares at $16 to...read more
Orphan disease biotech Versartis upsizes IPO and increases range to $19 to $21
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more